![Photo](/media/story/24944/thumbnail-01-cleveland-clinic.jpg)
News • Coronavirus
COVID-19: Enzyme blocks immune response to infection
Researchers from Cleveland Clinic’s Florida Research and Innovation Center (FRIC) have identified a potential new target for anti-COVID-19 therapies.
Researchers from Cleveland Clinic’s Florida Research and Innovation Center (FRIC) have identified a potential new target for anti-COVID-19 therapies.
Los investigadores acaban de establecer un nuevo acrónimo en español con el objetivo de crear un mayor nivel de conciencia en la comunidad hispana acerca de los síntomas de los ataques cerebrales. Conocido como RÁPIDO, la intención de este nuevo acrónimo es replicar el equivalente popular que existe en inglés de FAST. En los estudios se ha mostrado que hoy en día los adultos hispanos…
BOLD-100/KP1339 is a ruthenium-based anticancer agent that has been co-developed at the University of Vienna and which has shown promising results in clinical trials in cancer patients. However, the mode of action of this metal compound has not yet been fully elucidated. Researchers from the University of Vienna and the Medical University of Vienna have now been able to demonstrate that BOLD-100…
Hemodialysis patients routinely experience side effects such as fatigue, lightheadedness and nausea during their treatment sessions. But patients in a study who used a virtual reality program to engage in a mindfulness/meditation exercise reported that these treatment-related symptoms were greatly reduced. Patients in the study wore a head-mounted virtual reality display to participate in a…
Apheresis, a procedure that separates and removes particular blood constituents, shows promise for Covid-19 cases: the first patient successfully underwent so-called CRP apheresis, which can prevent potentially fatal consequences of the infection.
Doctors and healthcare workers may one day use a machine learning model, called deep learning, to guide their treatment decisions for lung cancer patients, according to a team of Penn State Great Valley researchers. In a study, the researchers report that they developed a deep learning model that, in certain conditions, was more than 71% accurate in predicting survival expectancy of lung cancer…
Researchers from the University of Nottingham have discovered a novel antiviral property of a drug that could have major implications in how future epidemics/pandemics – including Covid-19 – are managed. The study, published in Viruses, shows that thapsigargin is a promising broad‑spectrum antiviral, highly effective against SARS-CoV-2, a common cold coronavirus, respiratory syncytial virus…
As the first coronavirus vaccines started to be rolled out at the end of a tumultuous 2020, UK officials unexpectedly endorsed stretching the gap between the first and second vaccine dose by up to three months – an approach also considered by other countries.
One more piece of the puzzle has fallen into place behind a new drug whose anti-cancer potential was developed at the University of Alberta and is set to begin human trials this year, thanks to newly published research. “The results provide more justification and rationale for starting the clinical trial in May,” said first author John Mackey, professor and director of oncology clinical…
There is currently no cure for osteoarthritis, but a group of scientists believe they’ve discovered a method through which a simple knee injection could potentially stop the disease’s effects. These researchers showed that they could target a specific protein pathway in mice, put it into overdrive and halt cartilage degeneration over time. Building on that finding, they were able to show that…
Bacteria or viruses like influenza that cause pneumonia can spread across large regions of the lung within hours. In the modern intensive care unit, these bacteria or viruses are usually controlled either by antibiotics or by the body’s immune system within the first few days of the illness. But in a study published in Nature, investigators at Northwestern Medicine show Covid-19 pneumonia is…
A scalpel-free alternative to brain surgery has the potential to benefit people with Parkinson’s disease symptoms that are much more severe on one side of the body, new research suggests. More testing is needed, but the approach, which uses a technology called focused ultrasound, could offer a new option for patients whose symptoms are poorly controlled by medications and those who cannot or do…
A promising approach to treating cancer—called targeted alpha-particle therapy or TAT—could better harness the curative power of radiation treatments and lessen the severity of their more debilitating side effects.
A recent preclinical study from scientists at Sunnybrook Research Institute, Canadian Blood Services and the University of Toronto has demonstrated that focused ultrasound improves the delivery of intravenous immunoglobulin (IVIg), a blood product composed of antibodies from healthy donors, previously shown to have potential in treating a subgroup of patients with Alzheimer’s disease.
Electrophysiologists in Europe will now have access to state-of-the-art, gold-tipped force sensing ablation catheters following the Biotronik announcement that AlCath Force is CE-market approved. With the release of the unique catheter, a full suite of specialized tools for a complete solution in the treatment of complex atrial fibrillation (AF) cases is available to physicians.
A study of over a thousand cancer patients treated with immunotherapy drugs has found these patients are at greater risk of heart problems, including death from heart attack or stroke. The patients had either lung cancer or malignant melanoma (a type of skin cancer), for which immune checkpoint inhibitors such as a programmed cell death-1 (PD1) inhibitors or cytotoxic T-lymphocyte-associated…
In recent years, targeted therapies have cemented their place as some of the most important tools in cancer treatment. These medicines are designed to block specific signals that tumor cells use to grow and spread, while at the same time leaving normal cells unharmed. Targeted therapies can significantly extend patients’ lives, but the benefits are often only temporary. Over time, many cancers…
Researchers in Finland have developed a machine learning model that can help us treat cancer more effectively.
In a preclinical study, NIH scientists found that the commonly used antibiotic methacycline may be effective at combating the neurological problems caused by Zika virus infections.
"Molecular glue degraders" are a new class of cancer drugs, which "glue" cancer growth-promoting proteins directly to the molecular machinery of a cell's disposal system, leading to the subsequent degradation of the cancer-driving proteins and anti-tumor activity. Scientists from Heidelberg and USA have now deciphered another mechanism whereby a small molecule can degrade a…
Scientists report on their detailed look at B cells' presence inside tumors. B cells represent the other major arm of the adaptive immune system, besides T cells, and could offer opportunities for new treatments against some kinds of cancers.
Researchers at Tel Aviv University (TAU) have demonstrated that the CRISPR/Cas9 system is very effective in treating metastatic cancers, a significant step on the way to finding a cure for cancer.
The evolving area of immunotherapies in lung cancer and the role of iRecist treatment assessment protocols were investigated during a virtual session organised by the British Institute of Radiology (BIR). Consultant radiologist Dr Charlie Sayer, specialist in lung cancer imaging at the Brighton and Sussex University Hospitals Trust, South of England, focused on immunotherapies, the limitations of…
Pancreatic cancer has the worst survival rate of any cancers, with immunotherapies currently offering negligible treatment benefits for patients. To help identify new therapeutic approaches, researchers from the University of Oxford have been focusing on leukocyte infiltration as a prognostic marker of the disease. Their study and findings were outlined by Dr Shivan Sivakumar during a session…
An autoimmune side effect of immune checkpoint inhibitor (ICI) drugs could signal improved control of kidney cancer, according to a new study by researchers in UT Southwestern's Kidney Cancer Program (KCP).